Prab at 01:51, 26 September 2023

2023-09-26T01:51:03Z

New page

[[File:Ioxitalamic acid.png|thumb|Ioxitalamic acid]]
'''Ioxitalamic acid''', commonly recognized by its brand name '''Telebrix''', is an organoiodine compound specifically engineered for its use as a [[contrast medium]] in a multitude of diagnostic radiographic procedures. As an iodinated monomer molecule, ioxitalamic acid's distinguishing feature is its capability to enhance the clarity of medical images by absorbing X-rays more effectively than the tissues in the human body.

=== Chemical and Physical Properties ===
Ioxitalamic acid, like other members of the iodinated contrast media family, possesses a high iodine content, making it particularly effective at attenuating X-rays. The presence of iodine atoms in these molecules is crucial for their X-ray absorptive properties and hence their utility in radiographic imaging<ref>Cohan, R. H., Dunnick, N. R., & Leder, R. A. (1991). Intravascular contrast material administration in current radiologic practice: a comprehensive overview. ''Radiology'', 180(1), 13-21.</ref>.

=== Clinical Applications ===
Ioxitalamic acid's clinical applications span a wide range of imaging studies:
* [[Computed Tomography (CT)]] scans
* [[Angiography]]
* [[Hysterosalpingography]]
* Intravenous urography
This contrast agent significantly enhances the contrast between the organ of interest and its surrounding structures, thereby improving the diagnostic accuracy of the imaging study<ref>Manzke, R., Meyer, B. C., Frenzel, T., & Wedegärtner, U. (2019). Applications of ionic and nonionic contrast media in radiology. ''Rofo'', 191(1), 24-30.</ref>.

=== Pharmacokinetics ===
Post-intravascular administration, ioxitalamic acid quickly disperses into the extracellular fluid space. Predominantly, renal excretion facilitates its removal from the body. Hence, its clearance correlates directly with the renal function, making dosage adjustments necessary for patients with compromised renal function<ref>Barrett, B. J., & Parfrey, P. S. (2005). Clinical practice. Preventing nephropathy induced by contrast medium. ''The New England journal of medicine'', 352(3), 239-246.</ref>.

=== Safety Profile and Adverse Effects ===
While ioxitalamic acid is generally considered safe for most patients, it's crucial for clinicians to be vigilant for potential adverse reactions. Common side effects encompass:
* Flushing or warmth at the injection site
* Mild nausea
Severe reactions, though uncommon, may manifest as:
* [[Anaphylactic reactions]]
* [[Hypotension]]
* [[Respiratory distress]]
Such reactions necessitate immediate medical attention, and healthcare providers must be prepared to manage these potential complications<ref>Pannu, N., & Wiebe, N. (2008). Prophylaxis strategies for contrast-induced nephropathy. ''JAMA'', 299(23), 2773-2783.</ref>.
=== Conclusion ===
Ioxitalamic acid, with its robust contrast-enhancing properties, remains a cornerstone in modern radiological practices. Through its effective differentiation of bodily structures, it offers invaluable assistance in accurate disease diagnosis and assessment.
{{pharmacology-stub}}
{{Contrast media}}
== References ==
* Cohan, R. H., Dunnick, N. R., & Leder, R. A. (1991). Intravascular contrast material administration in current radiologic practice: a comprehensive overview. ''Radiology'', 180(1), 13-21.
* Manzke, R., Meyer, B. C., Frenzel, T., & Wedegärtner, U. (2019). Applications of ionic and nonionic contrast media in radiology. ''Rofo'', 191(1), 24-30.
* Barrett, B. J., & Parfrey, P. S. (2005). Clinical practice. Preventing nephropathy induced by contrast medium. ''The New England journal of medicine'', 352(3), 239-246.
* Pannu, N., & Wiebe, N. (2008). Prophylaxis strategies for contrast-induced nephropathy. ''JAMA'', 299(23), 2773-2783.
[[Category:Acetanilides]]
[[Category:Benzamides]]
[[Category:Benzoic acids]]
[[Category:Monomers]]
[[Category:Radiocontrast agents]]

Ioxitalamic acid - Revision history

Prab at 01:51, 26 September 2023